A new study has revealed that a drug commonly used to halt premature labour may be associated with brain damage and intestinal issues in premature babies.
When a woman goes into labour early, obstetricians are faced with the possibility of delivering a baby who is not ready to breathe on its own. Often the mother is given both a tocolytic agent, or drug used to stop labour, and a steroid to help the baby's lungs mature faster. After the baby has had a couple days to allow the steroid to work, the tocolytic agent is stopped and the mother can give birth shortly after.
"As pediatricians and neonatalogists, it's important for us to know whether the benefit of these drugs outweighs the potential for complications for these medically fragile children," said Sanjiv Amin, M.D., assistant professor of Pediatrics at the University of Rochester Medical Center and author of an article on the subject.
"In the case of the tocolytic agent indomethacin, we know it impacts blood flow but there have been no large randomized studies to evaluate the effects on the baby," Amin added.
The new analysis of a collection of studies, or a metaanalysis, by University of Rochester Medical Center researchers pulls together enough data to conclude that there is a link between use of indomethacin and babies experiencing periventricular leukomalacia (white matter injury by decreasing blood flow in the brain, which may lead to cerebral palsy).
The analysis also showed a link between indomethacin and necrotizing entercolitis (a condition in which intestinal tissue dies, which can sometimes be successfully treated with antibiotics but can require surgery and even cause death), especially for those babies who were exposed to the drug within days of birth.
However, use of antenatal indomethacin is not linked to intraventricular hemorrhage (bleeding in the brain), patent ductus arteriosus (a congenital heart defect), respiratory distress syndrome (a life-threatening lung disorder) or death.
Obstetricians often employ indomethacin only when women go into labour extremely early. But many obstetricians believe it is more effective and has fewer side effects for the mother than other commonly used tocolytic agents, and so they may use it for woman whose babies are farther along.
Christopher Glantz, M.D., M.P.H., professor of Obstetrics and Gynecology at the University of Rochester Medical Center and a co-author of the study, said he hopes the analysis will encourage obstetricians to use the drug only when women are in labour very early when their babies are at most risk of the problems related to pre-maturity.
"It's important for us to realize that these drugs are not benign," Glantz said. "None of the drugs we have to stop labour work all that well, and we're stuck between a rock - a premature baby who could benefit from more time in the womb - and a hard place - a baby who may develop problems because of drugs such as indomethacin that may provide extra time in the womb.
"We need to use the drug only on those who need it most," Glantz added. The study is published in American Journal of Obstetrics and Gynecology.